WallStreetZenWallStreetZen

NYSE: AORT
Artivion Inc Stock Forecast, Predictions & Price Target

Analyst price target for AORT

Based on 3 analysts offering 12 month price targets for Artivion Inc.
Min Forecast
$25.00-6.02%
Avg Forecast
$28.33+6.52%
Max Forecast
$30.00+12.78%

Should I buy or sell AORT stock?

Based on 3 analysts offering ratings for Artivion Inc.
Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their AORT stock forecasts and price targets.

AORT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-07-02
lockedlocked$00.00+00.00%2024-05-07Find Out Why
lockedlocked$00.00+00.00%2024-05-07

1 of 1

Forecast return on equity

Is AORT forecast to generate an efficient return?
Company
12.31%
Industry
22.48%
Market
62.99%
AORT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AORT forecast to generate an efficient return on assets?
Company
4.63%
Industry
11.82%
AORT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AORT earnings per share forecast

What is AORT's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$0.24
Avg 2 year Forecast
$0.40
Avg 3 year Forecast
$0.87

AORT revenue forecast

What is AORT's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$392.4M+6.56%
Avg 2 year Forecast
$429.6M+16.67%
Avg 3 year Forecast
$479.0M+30.09%
AORT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AORT revenue growth forecast

How is AORT forecast to perform vs Medical Devices companies and vs the US market?
Company
8.45%
Industry
8.13%
Market
9.9%
AORT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AORT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AORT vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
AORT$26.60$28.33+6.52%Strong Buy
SILK$27.06$23.10-14.63%Buy
AVNS$21.18N/AN/A
ESTA$45.63$58.25+27.66%Strong Buy
AHCO$10.47$13.00+24.16%Strong Buy

Artivion Stock Forecast FAQ

Is Artivion Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NYSE: AORT) stock is to Strong Buy AORT stock.

Out of 3 analysts, 2 (66.67%) are recommending AORT as a Strong Buy, 1 (33.33%) are recommending AORT as a Buy, 0 (0%) are recommending AORT as a Hold, 0 (0%) are recommending AORT as a Sell, and 0 (0%) are recommending AORT as a Strong Sell.

If you're new to stock investing, here's how to buy Artivion stock.

What is AORT's earnings growth forecast for 2024-2026?

(NYSE: AORT) Artivion's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 30.14%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 20.72%.

Artivion's earnings in 2024 is -$9,625,000.On average, 2 Wall Street analysts forecast AORT's earnings for 2024 to be $10,016,266, with the lowest AORT earnings forecast at $8,764,233, and the highest AORT earnings forecast at $11,268,299. On average, 2 Wall Street analysts forecast AORT's earnings for 2025 to be $16,485,105, with the lowest AORT earnings forecast at $10,850,955, and the highest AORT earnings forecast at $22,119,254.

In 2026, AORT is forecast to generate $36,308,965 in earnings, with the lowest earnings forecast at $36,308,965 and the highest earnings forecast at $36,308,965.

What is AORT's revenue growth forecast for 2024-2026?

(NYSE: AORT) Artivion's forecast annual revenue growth rate of 8.45% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.13%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.9%.

Artivion's revenue in 2024 is $368,206,000.On average, 2 Wall Street analysts forecast AORT's revenue for 2024 to be $16,374,508,319, with the lowest AORT revenue forecast at $16,351,554,376, and the highest AORT revenue forecast at $16,397,462,262. On average, 2 Wall Street analysts forecast AORT's revenue for 2025 to be $17,929,116,283, with the lowest AORT revenue forecast at $17,912,422,506, and the highest AORT revenue forecast at $17,945,810,060.

In 2026, AORT is forecast to generate $19,990,797,718 in revenue, with the lowest revenue forecast at $19,990,797,718 and the highest revenue forecast at $19,990,797,718.

What is AORT's forecast return on assets (ROA) for 2024-2026?

(NYSE: AORT) forecast ROA is 4.63%, which is lower than the forecast US Medical Devices industry average of 11.82%.

What is AORT's Price Target?

According to 3 Wall Street analysts that have issued a 1 year AORT price target, the average AORT price target is $28.33, with the highest AORT stock price forecast at $30.00 and the lowest AORT stock price forecast at $25.00.

On average, Wall Street analysts predict that Artivion's share price could reach $28.33 by Jul 2, 2025. The average Artivion stock price prediction forecasts a potential upside of 6.52% from the current AORT share price of $26.60.

What is AORT's Earnings Per Share (EPS) forecast for 2024-2026?

(NYSE: AORT) Artivion's current Earnings Per Share (EPS) is -$0.24. On average, analysts forecast that AORT's EPS will be $0.24 for 2024, with the lowest EPS forecast at $0.21, and the highest EPS forecast at $0.27. On average, analysts forecast that AORT's EPS will be $0.40 for 2025, with the lowest EPS forecast at $0.26, and the highest EPS forecast at $0.53. In 2026, AORT's EPS is forecast to hit $0.87 (min: $0.87, max: $0.87).

What is AORT's forecast return on equity (ROE) for 2024-2026?

(NYSE: AORT) forecast ROE is 12.31%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.